Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TS 23

Next Previous
Drug Profile

TS 23

Alternative Names: DS-9231; Stromab; TS23

Latest Information Update: 04 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Translational Sciences
  • Developer Daiichi Sankyo Company; Translational Sciences
  • Class Anti-ischaemics; Antithrombotics; Monoclonal antibodies; Vascular disorder therapies
  • Mechanism of Action Antiplasmin inhibitors; Fibrinolytic agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pulmonary embolism; Stroke
  • Phase I Myocardial infarction; Venous thrombosis
  • No development reported Thrombosis

Most Recent Events

  • 18 Mar 2024 Translational Sciences initiates enrolment in a phase II SISTER trial for Stroke in USA (NCT05948566)
  • 18 Jul 2023 Translational Sciences plans a phase II SISTER trial for Stroke in unknown location (NCT05948566)
  • 24 May 2023 Phase-II clinical trials in Pulmonary embolism in USA (IV) (CSL Behring pipeline, November 2022) (NCT05408546)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top